[go: up one dir, main page]

AU2013245630A1 - Treatment of ischemic retinopathies - Google Patents

Treatment of ischemic retinopathies Download PDF

Info

Publication number
AU2013245630A1
AU2013245630A1 AU2013245630A AU2013245630A AU2013245630A1 AU 2013245630 A1 AU2013245630 A1 AU 2013245630A1 AU 2013245630 A AU2013245630 A AU 2013245630A AU 2013245630 A AU2013245630 A AU 2013245630A AU 2013245630 A1 AU2013245630 A1 AU 2013245630A1
Authority
AU
Australia
Prior art keywords
angptl4
vegf
antagonist
dme
hif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013245630A
Other languages
English (en)
Inventor
Silvia MONTANER
Akrit SODHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Maryland Baltimore
Original Assignee
Johns Hopkins University
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, University of Maryland Baltimore, University of Maryland College Park filed Critical Johns Hopkins University
Publication of AU2013245630A1 publication Critical patent/AU2013245630A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013245630A 2012-04-13 2013-04-15 Treatment of ischemic retinopathies Abandoned AU2013245630A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623696P 2012-04-13 2012-04-13
US61/623,696 2012-04-13
PCT/US2013/036561 WO2013155512A2 (fr) 2012-04-13 2013-04-15 Traitement de rétinopathies ischémiques

Publications (1)

Publication Number Publication Date
AU2013245630A1 true AU2013245630A1 (en) 2014-10-30

Family

ID=49328289

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013245630A Abandoned AU2013245630A1 (en) 2012-04-13 2013-04-15 Treatment of ischemic retinopathies

Country Status (5)

Country Link
US (1) US20150071941A1 (fr)
EP (1) EP2836232A4 (fr)
AU (1) AU2013245630A1 (fr)
CA (1) CA2870341A1 (fr)
WO (1) WO2013155512A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (fr) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Anticorps se liant à la protéine tyrosine phosphatase béta humaine (hptp-beta) et leurs utilisations
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016020882A2 (fr) 2014-08-07 2016-02-11 Novartis Ag Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
SG10201805646WA (en) 2014-08-07 2018-08-30 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
WO2017117464A1 (fr) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Anticorps et conjugués de ceux-ci
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020223209A1 (fr) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Activateurs de tie -2 ciblant le canal de schlemm
WO2021072265A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
CN110613847B (zh) * 2019-10-23 2022-02-11 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN115175685B (zh) * 2019-12-09 2024-12-13 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007899B1 (fr) * 2006-03-20 2017-06-07 Celldex Therapeutics, Inc. Anticorps dirigés contre la protéine 4 du type angiopoiétine et utilisations de ceux-ci
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري

Also Published As

Publication number Publication date
CA2870341A1 (fr) 2013-10-17
WO2013155512A2 (fr) 2013-10-17
EP2836232A2 (fr) 2015-02-18
EP2836232A4 (fr) 2016-03-16
US20150071941A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
US20150071941A1 (en) Treatment of ischemic retinopathies
US20240301429A1 (en) Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
US20160185845A1 (en) Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
US12060619B2 (en) Treatment of angiogenesis disorders
Xiao et al. RTN4/Nogo-A-S1PR2 negatively regulates angiogenesis and secondary neural repair through enhancing vascular autophagy in the thalamus after cerebral cortical infarction
Zhu et al. YAP via interacting with STAT3 regulates VEGF-induced angiogenesis in human retinal microvascular endothelial cells
RU2736499C1 (ru) Специфические ингибиторы гексокиназы-2 для применения при остром повреждении центральной нервной системы
Dritsoula et al. Angiopathic activity of LRG1 is induced by the IL-6/STAT3 pathway
CN105435228A (zh) 三氧化二砷的抗肿瘤新用途及抗肿瘤制剂
Kobayashi et al. Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy
US20130333059A1 (en) Hox compositions and methods
Xu et al. Novel regulators of retina neovascularization: a proteomics approach
Lei et al. Deubiquitinase USP9X controls Wnt signaling for CNS vascular formation and barrier maintenance
Su et al. Endothelial TREM-1 mediates sepsis-induced blood‒brain barrier disruption and cognitive impairment via the PI3K/Akt pathway
Wu et al. Angiogenic and fibrogenic dual-effect of gremlin1 on proliferative diabetic retinopathy
Xu et al. Long noncoding RNA PPT2-EGFL8 regulates pathological retinal neovascularization in PDR by functioning as a competing endogenous RNA
CN104334195A (zh) 包含抑制scf或者其受体的物质的用于治疗或预防血管渗透性相关疾病的组合物
Zhang et al. YBX1-driven TUBB6 upregulation facilitates ocular angiogenesis via WNT3A-FZD8 pathway
US20250346635A1 (en) Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
Ho et al. Elevated VEGF receptor-2 abundance contributes to increased angiogenesis in VEGF receptor-1 deficient mice
Parmentier et al. Regulation of physiological and tumoral angiogenesis by the chemerin system
Huang The Roles of Hypoxia-Inducible Factor 1α (HIF-1α) in the Traumatic Brain Injury-Induced Neurogenesis
Trigger TLR2 Is a Primary Receptor for Alzheimer's
HK1193429A (en) Treatment of angiogenesis disorders
HK1193429B (en) Treatment of angiogenesis disorders

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted